Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 26.22B P/E 38.41 EPS this Y -13.20% Ern Qtrly Grth -70.00%
Income 4.2B Forward P/E 14.03 EPS next Y 90.90% 50D Avg Chg -6.00%
Sales 1.54T PEG 43,962.00 EPS past 5Y -6.56% 200D Avg Chg -1.00%
Dividend 398.00% Price/Book 0.02 EPS next 5Y 0.11% 52W High Chg -14.00%
Recommedations 2.00 Quick Ratio 0.69 Shares Outstanding 1.79B 52W Low Chg 14.00%
Insider Own 0.25% ROA 2.48% Shares Float 1.79B Beta 0.28
Inst Own 52.69% ROE 0.27% Shares Shorted/Prior -/- Price 14.60
Gross Margin 81.76% Profit Margin 0.27% Avg. Volume 1,530 Target Price -
Oper. Margin 4.47% Earnings Date - Volume 250 Change -3.07%
About ASTELLAS PHARMA

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.

ASTELLAS PHARMA News
03/28/24 China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
03/26/24 Astellas Receives Permanent J-code for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
03/26/24 Astellas' VYLOY™ (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer
03/22/24 Astellas Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting
03/20/24 Q4 2023 Taysha Gene Therapies Inc Earnings Call
03/19/24 With new data, Bayer readies rival to Astellas menopause drug
03/11/24 FDA Grants Orphan Drug and Pediatric Exclusivities for CRESEMBA® (isavuconazonium sulfate) for Invasive Aspergillosis and Invasive Mucormycosis in Children
03/03/24 Astellas Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan
02/16/24 Astellas teams up with startup Kelonia to make ‘in vivo’ cell therapies
02/15/24 PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) Granted Priority Review by Japan's Ministry of Health, Labour and Welfare for First-Line Treatment of Advanced Bladder Cancer
02/15/24 Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeutics
02/06/24 Astellas Makes Announcement about Management Structure
02/01/24 Astellas to Air New VEOZAH® (fezolinetant) TV Spot During the Super Bowl
01/30/24 Astellas Submits Supplemental New Drug Application in Japan for PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) for First-Line Treatment of Advanced Bladder Cancer
01/30/24 Astellas Announces Strategic Collaboration with Mass General Brigham
01/26/24 European Medicines Agency Validates Type II Variation Application for PADCEV™ (enfortumab vedotin) with KEYTRUDA®(pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
01/08/24 US FDA declines to approve Astellas' gastric cancer drug
01/08/24 Astellas Provides Update on Zolbetuximab Biologics License Application in U.S.
12/28/23 Elpiscience and Astellas Enter into Research Collaboration and License Agreement for Novel Bispecific Macrophage Engager
12/21/23 Astellas Completes Acquisition of Propella Therapeutics